Comparison
CagriSema vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
910463-68-2
Molecular weight
no data
4113.6 g/mol
Half-life
no data
165 h
Sequence
no data
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
3
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
5
Legal status
Full entries
Frequently asked questions
- What is the difference between CagriSema and Semaglutid?
- CagriSema is classified as "Metabolic", while Semaglutid is classified as "Metabolic". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Semaglutid?
- The highest available evidence level is "Human RCT" for CagriSema and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Semaglutid in Germany and the United States?
- Germany: CagriSema — Unapproved, Semaglutid — Prescription. United States: CagriSema — Unapproved, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.